ClinicalTrials.gg
CompletedNCT02752906Updated Apr 5, 2022Results posted

Immunogenicity and Safety of a Booster Dose of an Investigational Quadrivalent Meningococcal Conjugate Vaccine

A Phase 3 interventional study of Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine and Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine in Meningitis, Meningococcal Meningitis and Meningococcal Infections, sponsored by Sanofi Pasteur, a Sanofi Company. Completed at 30 sites in 2 countries. Open to participants aged 15 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-04-05.

Primary conditionMeningitis, MeningococcalRegistry: MeningitisReclassifiedWhy we changed it
Registry
Meningitis — the first condition term the registry derived for this study.
ClinicalTrials.gg
Meningitis, Meningococcal
Why
  1. The study's listed conditions name Meningitis, Meningococcal, a narrower term within Meningitis.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Sanofi Pasteur, a Sanofi Company (part of Sanofi) · Phase 3, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
810
Allocation
Randomized
Ages
15 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 24 studies in Meningitis, Meningococcal by Sanofi — none open to participants now, none under way, none of them phase 3. Meningitis, Meningococcal · Sanofi.

Enrollment
14th of 23
810 · median 907
Started
2016
with 6 others
Phase 3
13 of 24
none open now
Registered
14th of 24
by date

Among the 24 studies in Meningitis, Meningococcal by Sanofi, this one is the 14th largest by enrollment of the 23 interventional ones that give a count, is one of 7 that started in 2016, is one of 13 in phase 3, and was the 14th registered.

Meningitis, Meningococcal

125 studies on the registry are indexed under Meningitis, Meningococcal; 10 are open to participants now.

Browse Meningitis, Meningococcal studies →

Open to participants now

None of the 24 studies in Meningitis, Meningococcal by Sanofi is open now. The open studies under Meningitis, Meningococcal, anywhere →

Who these studies take

Of the 5 Meningitis, Meningococcal studies recruiting now, none set no upper age limit and 5 stop at 75 or younger; 4 take children under 18; 5 take healthy volunteers.

This study: 15 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 24 studies in Meningitis, Meningococcal by Sanofi as a file.
02

Study summary

The aim of the study was to describe the safety and antibody response to booster administration with Meningococcal Polysaccharide (Serogroups A, C, Y and W) Tetanus Toxoid (MenACYW) Conjugate vaccine in participants who received their first quadrivalent meningococcal Conjugate vaccine dose in the past 4-10 years.

Primary Objective:

  • To demonstrate the non-inferiority of the vaccine seroresponse of meningococcal serogroups A, C, Y, and W following the administration of a booster dose of MenACYW Conjugate vaccine compared to those observed following the administration of a booster dose of Menactra® in participants who were first vaccinated with 1 dose of a quadrivalent meningococcal vaccine 4 to 10 years before the booster dose.

Secondary Objectives:

  • To evaluate the vaccine seroresponse of meningococcal serogroups A, C, Y, and W measured using human serum bactericidal assay (hSBA) in serum specimens collected 6 days after vaccination in a subset of 120 participants.
  • To evaluate the antibody responses (geometric mean titers) to serogroups A, C, Y, and W measured using hSBA on Day 0 (pre-vaccination) and Day 30 after vaccination.

Observational Objectives:

  • To describe the antibody titers against meningococcal serogroups A, C, Y, and W measured by hSBA assessed at Day 0, Day 6, and Day 30 days after vaccination.
  • To describe the antibody responses to the meningococcal serogroups A, C, Y, and W before and 30 days after vaccination with MenACYW Conjugate vaccine or Menactra® measured by rabbit serum bactericidal assay (rSBA) in a subset of participants.
  • To describe the safety profile of MenACYW Conjugate vaccine compared to that of a licensed Menactra® after booster vaccination.
Read the detailed description

Healthy adolescents and adults who had received 1 dose of a quadrivalent meningococcal Conjugate vaccine 4 to 10 years previously were randomized to receive either 1 dose of MenACYW Conjugate vaccine or licensed Menactra®. All participants underwent immunogenicity assessment at baseline (pre-vaccination) and post-vaccination and were also evaluated for safety up to Day 180 post-vaccination. In addition, a subset had an additional blood sample collected at 6 days post-vaccination for immunogenicity assessment.

03

Conditions studied

  • Meningitis
  • Meningococcal Meningitis
  • Meningococcal Infections

Browse trials for

Keywords

  • Meningitis
  • Meningococcal Meningitis
  • Meningococcal Infections
  • MenACYW Conjugate vaccine
  • Licensed Meningococcal Conjugate Vaccine (MCV4)
04

In context

Meningitis, Meningococcal Reclassified

125 studies on the registry are indexed under Meningitis, Meningococcal; 10 are open to participants now.

This study's enrollment of 810 is above the median of 538 across 113 interventional studies indexed under Meningitis, Meningococcal.

Browse Meningitis, Meningococcal studies →

Lead sponsor

Sanofi Pasteur, a Sanofi Company is the lead sponsor of 374 studies on the registry; 4 are open to participants now.

Of its 94 completed or terminated interventional studies of FDA-regulated products, 73 (78%) have results posted.

First submitted after Sanofi Pasteur became part of Sanofi.

Compared within Meningitis, Meningococcal, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Meningitis. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
15 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged >= 15 years on the day of inclusion.
  • Participant has documented record of having received 1 dose of a quadrivalent meningococcal conjugate vaccine 4 to 10 years prior to study vaccination.
  • Participant aged 15 to \< 18 years: assent form signed and dated by the participant and form (ICF) signed and dated by the parent or guardian.
  • Participant aged >=18 years: ICF signed and dated by the participant.
  • Participants aged 15 to \< 18 years: both the participant and parent / guardian were able to attend all scheduled visits and to comply with all trial procedures.
  • Participants aged >= 18 years: able to attend all scheduled visits and to comply with all trial procedures.

Exclusion criteria

Exclusion Criteria:

  • Participant was pregnant, lactating, or of (to be considered of non-childbearing potential, a female must be pre-menarche or for at least 1 year, surgically sterile, or using an effective method of or abstinence from at least 4 weeks prior to vaccination until at least 4 weeks after vaccination).
  • Participation in the 4 weeks preceding the trial vaccination or planned participation during the present trial period in another clinical trial investigating a vaccine, drug, medical device, or medical procedure.
  • Receipt of any vaccine in the 4 weeks (28 days) preceding the trial vaccination or planned receipt of any vaccine before Day 30 visit except for influenza vaccination, which may be received at least 2 weeks before study vaccines. This exception includes monovalent pandemic influenza vaccines and multivalent influenza vaccines.
  • Previous vaccination against meningococcal disease with either an investigational or approved meningococcal B vaccine.
  • Receipt of immune globulins, blood or blood-derived products in the past 3 months.
  • Known or suspected congenital or acquired immunodeficiency; or receipt of therapy, such as anti-cancer chemotherapy or radiation therapy, within the preceding 6 months; or long-term systemic therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months).
  • History of meningococcal infection, confirmed either clinically, serologically, or microbiologically.
  • At high risk for meningococcal infection during the trial (specifically, but not limited to, participants with persistent complement deficiency, with anatomic or functional asplenia, or participants travelling to countries with high endemic or epidemic disease).
  • Known systemic to any of the vaccine components, or history of a life-threatening reaction to the vaccine(s) used in the trial or to a vaccine containing any of the same substances.
  • Personal history of an Arthus-like reaction after vaccination with a tetanus toxoid-containing vaccine.
  • Personal history of Guillain-Barré syndrome.
  • Verbal report of thrombocytopenia, contraindicating intramuscular vaccination in the Investigator's opinion.
  • Bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating intramuscular vaccination in the Investigator's opinion.
  • Deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized involuntarily.
  • Current alcohol abuse or drug addiction.
  • Chronic illness that, in the opinion of the investigator, is at a stage where it might interfere with trial conduct or completion.
  • Moderate or severe acute illness/infection (according to the Investigator's judgment) on the day of vaccination or febrile illness (temperature >= 100.4°Fahrenheit [F]). A prospective participant should not be included in the study until the condition has resolved or the febrile event has subsided.
  • Receipt of oral or injectable antibiotic therapy within 72 hours prior to the first blood draw.
  • Identified as an Investigator or employee of the Investigator or study center with direct involvement in the proposed study, or identified as an immediate family member (i.e., parent, spouse, natural or adopted child) of the Investigator or employee with direct involvement in the proposed study.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

06

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
810 participants (actual)

Study arms

  • Experimental
    MenACYW Conjugate Vaccine

    Healthy, meningococcal vaccine-primed adolescents (greater than or equal to \[\>=\] 15 to less than \[\< \]18 years) or adults (\>= 18 years) received a single dose of a MenACYW Conjugate vaccine on Day 0.

    Biological: Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine

  • Active comparator
    Menactra®

    Healthy, meningococcal- vaccine-primed adolescents (\>= 15 to \< 18 years) or adults (\>= 18 years) received a single dose of Menactra ® vaccine on Day 0.

    Biological: Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine

Interventions

  • BiologicalMeningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine

    0.5 milliliter (mL), Intramuscular

    Also known as: MenACYW Conjugate vaccine

  • BiologicalMeningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine

    0.5 mL, Intramuscular

    Also known as: Menactra®

07

What researchers measure

Primary outcomes

  1. Percentage of Participants With Seroresponse to Meningococcal Serogroups A, C, Y, and W Following Vaccination With Either MenACYW Conjugate Vaccine or Menactra® Vaccine

    The serum bactericidal assay using human complement (hSBA) vaccine seroresponse for serogroups A, C, Y, and W was defined as post-vaccination hSBA titers \>= 1:16 for participants with pre-vaccination hSBA titers \< 1:8 or at least a 4-fold increase in hSBA titers from pre- to post-vaccination for participants with pre-vaccination hSBA titers \>= 1:8.

    Time frame: Day 30 (post-vaccination)

Secondary outcomes

  1. Percentage of Participants With Seroresponse to Meningococcal Serogroups A, C, Y, and W Following Vaccination With Either MenACYW Conjugate Vaccine or Menactra® Vaccine at Day 6 After Vaccination

    The hSBA vaccine seroresponse for serogroups A, C, Y, and W was defined as post-vaccination hSBA titers \>= 1:16 for participants with pre-vaccination hSBA titers \< 1:8 or at least a 4-fold increase in hSBA titers from pre- to post-vaccination for participants with pre-vaccination hSBA titers \>= 1:8.

    Time frame: Day 6 (post-vaccination)

  2. Geometric Mean Titers Against Meningococcal Serogroups A, C, Y, and W Antibodies Following Vaccination With Either MenACYW Conjugate Vaccine or Menactra® Vaccine

    Meningococcal antibody responses against Serogroups A, C, Y, and W were measured by hSBA.

    Time frame: Day 30 (post-vaccination)

  3. Number of Participants With Solicited Injection Site Reactions or Systemic Reactions Following Vaccination With Either MenACYW Conjugate Vaccine or Menactra® Vaccine

    A Solicited Reaction (SR) was an Adverse Event (AE) that was prelisted (i.e., solicited) in the electronic case report form (eCRF) and considered to be related to vaccination (adverse drug reaction). Solicited injection site reactions: Pain (Grade 1: no interference with activity, Grade 2: some interference with activity, Grade 3: significantly prevent daily activity), erythema and swelling (Grade 1: \>=25 millimeter \[mm\] to \<= 50 mm, Grade 2: \>=51 to \<=100 mm, Grade 3: \> 100 mm). Solicited systemic reactions: Fever (Grade 1: \>=38.0 degree Celsius (°C) to \<=38.4°C, Grade 2: \>=38.5°C to \<=38.9 °C, Grade 3: \>= 39°C), headache, malaise, and myalgia (Grade 1: no interference with activity, Grade 2: some interference with activity, Grade 3: significant; prevents daily activity. Number of participants with any of the Grade (1, 2 or 3) and with each Grade (1, 2 and 3) solicited injection-site and systemic reactions were reported.

    Time frame: Within 7 days post-vaccination

08

Results

Posted Jun 5, 2020

Participant flow

Study participants were enrolled in 30 centers from 15 April 2016 to 02 August 2016.

Participant flow — Overall Study
MilestoneMenACYW Conjugate VaccineMenactra ®
Started403407
Vaccinated402407
Completed396402
Not completed75
Withdrew: Protocol violation21
Withdrew: Withdrawal by subject22
Withdrew: Lost to follow-up32

Outcome measures

PrimaryPercentage of Participants With Seroresponse to Meningococcal Serogroups A, C, Y, and W Following Vaccination With Either MenACYW Conjugate Vaccine or Menactra® Vaccine

The serum bactericidal assay using human complement (hSBA) vaccine seroresponse for serogroups A, C, Y, and W was defined as post-vaccination hSBA titers \>= 1:16 for participants with pre-vaccination hSBA titers \< 1:8 or at least a 4-fold increase in hSBA titers from pre- to post-vaccination for participants with pre-vaccination hSBA titers \>= 1:8.

Time frame:
Day 30 (post-vaccination)
Reported as:
Number · percentage of participants
Percentage of Participants With Seroresponse to Meningococcal Serogroups A, C, Y, and W Following Vaccination With Either MenACYW Conjugate Vaccine or Menactra® Vaccine
percentage of participantsMenACYW Conjugate VaccineMenactra ®
Serogroup A92.2 (89.0 to 94.7)87.1 (83.4 to 90.3)
Serogroup C97.1 (94.9 to 98.6)91.8 (88.6 to 94.3)
Serogroup Y97.4 (95.3 to 98.7)95.6 (93.1 to 97.4)
Serogroup W98.2 (96.3 to 99.3)90.7 (87.4 to 93.4)
Statistical analysis
  • MenACYW Conjugate Vaccine vs Menactra ® · Percentage difference: 5.0 · 95% CI 0.735 to 9.38
  • MenACYW Conjugate Vaccine vs Menactra ® · Percentage difference: 5.4 · 95% CI 2.16 to 8.76
  • MenACYW Conjugate Vaccine vs Menactra ® · Percentage difference: 1.8 · 95% CI -0.907 to 4.55
  • MenACYW Conjugate Vaccine vs Menactra ® · Percentage difference: 7.4 · 95% CI 4.30 to 10.9
SecondaryPercentage of Participants With Seroresponse to Meningococcal Serogroups A, C, Y, and W Following Vaccination With Either MenACYW Conjugate Vaccine or Menactra® Vaccine at Day 6 After Vaccination

The hSBA vaccine seroresponse for serogroups A, C, Y, and W was defined as post-vaccination hSBA titers \>= 1:16 for participants with pre-vaccination hSBA titers \< 1:8 or at least a 4-fold increase in hSBA titers from pre- to post-vaccination for participants with pre-vaccination hSBA titers \>= 1:8.

Time frame:
Day 6 (post-vaccination)
Reported as:
Number · percentage of participants
Percentage of Participants With Seroresponse to Meningococcal Serogroups A, C, Y, and W Following Vaccination With Either MenACYW Conjugate Vaccine or Menactra® Vaccine at Day 6 After Vaccination
percentage of participantsMenACYW Conjugate VaccineMenactra ®
Serogroup A72.7 (59.0 to 83.9)66.1 (53.0 to 77.7)
Serogroup C83.6 (71.2 to 92.2)87.1 (76.1 to 94.3)
Serogroup Y90.9 (80.0 to 97.0)83.9 (72.3 to 92.0)
Serogroup W94.5 (84.9 to 98.9)83.9 (72.3 to 92.0)
SecondaryGeometric Mean Titers Against Meningococcal Serogroups A, C, Y, and W Antibodies Following Vaccination With Either MenACYW Conjugate Vaccine or Menactra® Vaccine

Meningococcal antibody responses against Serogroups A, C, Y, and W were measured by hSBA.

Time frame:
Day 30 (post-vaccination)
Reported as:
Geometric mean · titers (1/dilution)
Geometric Mean Titers Against Meningococcal Serogroups A, C, Y, and W Antibodies Following Vaccination With Either MenACYW Conjugate Vaccine or Menactra® Vaccine
titers (1/dilution)MenACYW Conjugate VaccineMenactra ®
Serogroup A497 (436 to 568)296 (256 to 343)
Serogroup C2618 (2227 to 3078)599 (504 to 711)
Serogroup Y2070 (1807 to 2371)811 (699 to 941)
Serogroup W1747 (1508 to 2025)723 (614 to 853)
SecondaryNumber of Participants With Solicited Injection Site Reactions or Systemic Reactions Following Vaccination With Either MenACYW Conjugate Vaccine or Menactra® Vaccine

A Solicited Reaction (SR) was an Adverse Event (AE) that was prelisted (i.e., solicited) in the electronic case report form (eCRF) and considered to be related to vaccination (adverse drug reaction). Solicited injection site reactions: Pain (Grade 1: no interference with activity, Grade 2: some interference with activity, Grade 3: significantly prevent daily activity), erythema and swelling (Grade 1: \>=25 millimeter \[mm\] to \<= 50 mm, Grade 2: \>=51 to \<=100 mm, Grade 3: \> 100 mm). Solicited systemic reactions: Fever (Grade 1: \>=38.0 degree Celsius (°C) to \<=38.4°C, Grade 2: \>=38.5°C to \<=38.9 °C, Grade 3: \>= 39°C), headache, malaise, and myalgia (Grade 1: no interference with activity, Grade 2: some interference with activity, Grade 3: significant; prevents daily activity. Number of participants with any of the Grade (1, 2 or 3) and with each Grade (1, 2 and 3) solicited injection-site and systemic reactions were reported.

Time frame:
Within 7 days post-vaccination
Reported as:
Count of participants · Participants
Number of Participants With Solicited Injection Site Reactions or Systemic Reactions Following Vaccination With Either MenACYW Conjugate Vaccine or Menactra® Vaccine
ParticipantsMenACYW Conjugate VaccineMenactra ®
Pain-Any Grade178196
Pain-Grade 1141154
Pain-Grade 23334
Pain-Grade 348
Erythema-Any Grade206
Erythema-Grade 1185
Erythema-Grade 221
Erythema-Grade 300
Swelling-Any Grade163
Swelling-Grade 1131
Swelling-Grade 232
Swelling-Grade 300
Fever-Any Grade02
Fever-Grade 100
Fever-Grade 201
Fever-Grade 301
Headache-Any Grade151134
Headache-Grade 19073
Headache-Grade 25247
Headache-Grade 3914
Malaise-Any Grade110108
Malaise-Grade 16264
Malaise-Grade 23730
Malaise-Grade 31114
Myalgia-Any Grade146156
Myalgia-Grade 198120
Myalgia-Grade 24027
Myalgia-Grade 389

Adverse events

Collected over Adverse event (AE) data were collected from Day 0 up to Day 30 post-vaccination. Solicited Reaction (SR) were collected from Day 0 up to Day 7 post-vaccination.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Group 1: MenACYW Conjugate Vaccine0/402 (0%)5/402 (1.2%)255/402 (63.4%)
Group 2: Menactra ®0/407 (0%)4/407 (1%)263/407 (64.6%)
Most frequent serious events
Most frequent serious events
EventGroup 1: MenACYW Conjugate VaccineGroup 2: Menactra ®
CholelithiasisHepatobiliary disorders1/4020/407
Allergy To Arthropod StingImmune system disorders1/4020/407
AppendicitisInfections and infestations1/4020/407
Clavicle FractureInjury, poisoning and procedural complications1/4020/407
Pulmonary EmbolismRespiratory, thoracic and mediastinal disorders1/4020/407
Intestinal PerforationGastrointestinal disorders0/4021/407
Chest PainGeneral disorders0/4021/407
Major DepressionPsychiatric disorders0/4021/407
Suicidal IdeationPsychiatric disorders0/4021/407
Most frequent other events
Most frequent other events
EventGroup 1: MenACYW Conjugate VaccineGroup 2: Menactra ®
Injection Site PainGeneral disorders178/402196/407
MyalgiaMusculoskeletal and connective tissue disorders147/402158/407
HeadacheNervous system disorders155/402137/407
MalaiseGeneral disorders110/402108/407

Baseline characteristics

Analysis was performed on all randomized participants.

Age, Continuous
Age, Continuous(Years)MenACYW Conjugate VaccineMenactra ®Total
Mean20.0 ± 5.9619.9 ± 5.5920.0 ± 5.77
Sex: Female, Male
Sex: Female, Male(Participants)MenACYW Conjugate VaccineMenactra ®Total
Female207200407
Male196207403
Race (NIH/OMB)
Race (NIH/OMB)(Participants)MenACYW Conjugate VaccineMenactra ®Total
American Indian or Alaska Native101
Asian11314
Native Hawaiian or Other Pacific Islander011
Black or African American404686
White342340682
More than one race81725
Unknown or Not Reported101
Region of Enrollment
Region of Enrollment(Participants)MenACYW Conjugate VaccineMenactra ®Total
United States403407810
09

Study locations

30 sites
  • Investigational Site Number 016
    Birmingham, Alabama 35205, United States
  • Investigational Site Number 032
    Dothan, Alabama 36305, United States
  • Investigational Site Number 026
    Mesa, Arizona 85213, United States
  • Investigational Site Number 022
    Jonesboro, Arkansas 72401, United States
  • Investigational Site Number 005
    Downey, California 90241, United States
  • Investigational Site Number 014
    La Puente, California 91744, United States
  • Investigational Site Number 029
    San Diego, California 92108, United States
  • Investigational Site Number 001
    San Diego, California 92123-1881, United States
  • Investigational Site Number 013
    Bardstown, Kentucky 40004, United States
  • Investigational Site Number 027
    Nicholasville, Kentucky 40356, United States
  • Investigational Site Number 015
    Metairie, Louisiana 70006, United States
  • Investigational Site Number 018
    Woburn, Massachusetts 01801, United States
  • Investigational Site Number 010
    Troy, Michigan 48098, United States
  • Investigational Site Number 008
    Kansas City, Missouri 64114, United States
  • Investigational Site Number 028
    Saint Louis, Missouri 63141, United States
  • Investigational Site Number 023
    Lincoln, Nebraska 68504, United States
  • Investigational Site Number 031
    Omaha, Nebraska 68144, United States
  • Investigational Site Number 006
    Rochester, New York 14609, United States
  • Investigational Site Number 012
    Fargo, North Dakota 58104, United States
  • Investigational Site Number 019
    Cincinnati, Ohio 45245, United States
  • Investigational Site Number 011
    Fairfield, Ohio 45014, United States
  • Investigational Site Number 025
    Huber Heights, Ohio 45424, United States
  • Investigational Site Number 021
    Kettering, Ohio 45429, United States
  • Investigational Site Number 009
    Erie, Pennsylvania 16508, United States
  • Investigational Site Number 007
    Hermitage, Pennsylvania 16148, United States
  • Investigational Site Number 024
    Tullahoma, Tennessee 37388, United States
  • Investigational Site Number 020
    Salt Lake City, Utah 84109, United States
  • Investigational Site Number 003
    Salt Lake City, Utah 84121, United States
  • Investigational Site Number 017
    South Jordan, Utah 84095, United States
  • Investigational Site Number 030
    San Juan, 00981, Puerto Rico
10

References and documents

Publications

  • Anez G, Hedrick J, Simon MW, Christensen S, Jeanfreau R, Yau E, Pan J, Jordanov E, Dhingra MS. Immunogenicity and safety of a booster dose of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in adolescents and adults: a Phase III randomized study. Hum Vaccin Immunother. 2020 Jun 2;16(6):1292-1298. doi: 10.1080/21645515.2020.1733867. Epub 2020 Mar 25. PubMed 32209015 ↗

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2016 to primary completion in Dec 2016, 8 months.

Results were first posted in Jun 2020, 3 years 5 months after primary completion. A results delay was requested in Jan 2018.

Of 25 phase 3 interventional studies under Meningitis, Meningococcal, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 20. This study's 8 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 22, 2016
First posted
Apr 27, 2016
StartActual
Apr 15, 2016
Primary completionActual
Dec 19, 2016
CompletionActual
Dec 19, 2016
Results delay requested
Jan 15, 2018
Results first posted
Jun 5, 2020
Last update
Apr 5, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 5, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT02752906
Responsible party
Sponsor
First posted
Apr 27, 2016
Start date
Apr 15, 2016
Primary completion
Dec 19, 2016
Completion
Dec 19, 2016
Results posted
Jun 5, 2020
Last update
Apr 5, 2022

Study contacts

Medical Director
study director · Sanofi Pasteur Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion